Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients. Venetoclax was available prior to approval off-label. We assessed our single-institution off-label experience with venetoclax/azacitidine, comparing outcomes with a clinical trial cohort that administered this regimen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Winters, Amanda C., Gutman, Jonathan A., Purev, Enkhtsetseg, Nakic, Molly, Tobin, Jennifer, Chase, Stephanie, Kaiser, Jeff, Lyle, Lindsey, Boggs, Chelsey, Halsema, Keri, Schowinsky, Jeffrey T., Rosser, Julie, Ewalt, Mark D., Siegele, Bradford, Rana, Vishal, Schuster, Steven, Abbott, Diana, Stevens, Brett M., Jordan, Craig T., Smith, Clayton, Pollyea, Daniel A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2019
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849960/
https://ncbi.nlm.nih.gov/pubmed/31648312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000243
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky